Immuron Says Fiscal Q1 Global Sales of Over-the-Counter Immune Supplement Up 34% Year-over-Year, Shares Fall 6%
MT Newswires Live
Oct 13, 2025
Immuron (ASX:IMC) reported sales of AU$1.6 million for its over-the-counter immune supplement Travelan in Australia for the fiscal first quarter was up 52% year-over-year, and sales of AU$2 million globally, increasing 34% from the prior corresponding period, according to a Monday Australian bourse filing.
The continued growth in Australia can be attributed to "increased awareness and consideration" driven by marketing, as well as same-store growth as a result of market promotions.
Its shares fell 6% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.